The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate-and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 1993 to June 1996, 14 consecutive patients entered this singlecenter prospective pilot trial. Patients were five males and nine females, median age 63 (range 61-65). The first-line treatment consisted of three courses of CHOP therapy. Patients achieving either a partial response (PR) or a complete response (CR) after initial therapy were eligible for PBSCT, while those with refractory or progessive disease were not autografted but included in the feasibility study in an intent-to-treat analysis. Of the 14 patients, 11 achieved either a CR (one) or a PR (10) after three courses of CHOP while the three patients with no response were not autografted and subsequently died of progressive disease. PBSC collection was feasible in responding patients after G-CSF priming (10 g/kg/day for 6 days). Conditioning therapy was the BEAM protocol. All patients engrafted after PBSCT. The median time to granulocyte (Ͼ0.5 × 10 9 /l) and platelet recovery (Ͼ25 × 10 9 /l) was 12 (range 9-18) and 13 days (range 7-22), respectively. No toxic deaths VOD or IP were observed. Four of the 11 responding patients relapsed 2, 7, 9 and 12 months after PBSCT, respectively, and all died from progressive disease. Overall, 7/14 patients are alive and free from disease, 16-43 months after initial diagnosis (median 28). The actuarial overall survival is 45.7 %, and the actuarial event-free survival is 50% at 3.5 years. This study shows the feasibility of high-dose therapy and PBSCT in patients with intermediate-or high-grade disseminated NHL aged 61-65 years. Such patients should not be excluded from trials evaluating the role of ASCT as part of initial treatment for disseminated and histologically aggressive NHL.
High-dose therapy with autologous stem cell transplantation (ASCT) may be considered the treatment of choice in patients with intermediate-or high-grade non-Hodgkin's lymphoma (NHL) who relapse after primary therapy. [1] [2] [3] This procedure is now being increasingly used as part of initial therapy for some groups of patients. [4] [5] [6] [7] [8] [9] However, ASCT is usually restricted to patients aged р60 years, partly due to the anticipated poor tolerance of intensive treatment in elderly patients. Recent results of high-dose therapy followed by peripheral blood stem cell transplantation (PBSCT) have shown marked reductions in treatment-related toxicity as compared to historical reports of autologous bone marrow transplantation (ABMT). Indeed, ASCT may become applicable to a subgroup of patients currently excluded from such trials, ie patients aged 61-65 years. It is all the more important as the median age of patients with NHL ranges from 60 to 65 years, 10 and age by itself is one of the most powerful prognostic factors in intermediate-and high-grade NHL. [11] [12] [13] Thus, in order to answer the question about the feasibility of PBSCT as front-line treatment up to the age of 65 years, we conducted a single-center prospective pilot study of such therapy in patients with aggressive NHL aged Ͻ60-65 years.
Patients and methods

Inclusion criteria and study design
From October 1993 to June 1996, all consecutive patients aged Ͼ60-65 years with disseminated stage III-IV intermediate-or high-grade NHL were considered eligible to receive high-dose therapy and PBSCT as front-line treatment, provided that they signed an informed consent. Patients with mantle-cell, lymphoblastic or diffuse small non-cleaved cell lymphomas were excluded from the analysis. The study design was as follows. First-line treatment consisted of three consecutive courses of CHOP therapy. 14 Patients achieving either a partial response (PR) or a complete response, (CR) 1 after initial therapy were eligible for PBSCT, while patients with refractory or progressive disease were not autografted but were included in the feasibility study in an intent-to-treat analysis. In responding patients, peripheral blood stem cells (PBSC) were collected after haematological recovery from the third course of CHOP regimen after G-CSF priming (10 g/kg/day for 6 days). An additional fourth course of CHOP was administered after stem cell collection and before intensive therapy.
The conditioning regimen was with the BEAM protocol (BCNU 300 mg/m 2 in 3-h infusion at day −7, cytarabine 400 mg/m 2 /day in continuous infusion from days −6 to −3, etoposide 100 mg/m 2 in 2-h infusions twice a day from days −6 to −3, melphalan 140 mg/m 2 in 30-min infusion at day −2) followed by PBSC reinfusion on day 0.
Patient characteristics
Fourteen consecutive patients were included in this study (Table 1) , five males and nine females, median age 63 (range 61-65). According to risk groups defined by the International Index and the age-adjusted index, 11 the majority of patients (11 out of 14) were considered as being in the high-intermediate group (Table 2) .
Supportive care
All patients were housed in laminar air-flow rooms. Parenteral broad-spectrum antibiotics were administered at time of first fever, and irradiated blood products were used to maintain the hemoglobin level above 8 g/dl and platelet count above 20 × 10 9 /l. Granulocyte colony-stimulating factor (5 g/kg/day) was administered from day 7 after PBSCT in all cases. 
Survival analysis
Actuarial overall and event-free survival curves were constructed according to the Kaplan and Meier method. 16 According to an intent-to-treat analysis, overall survival (OS) was calculated for all patients from the date of diagnosis to the date of death or last follow-up (September 1997). Event-free survival (EFS) was calculated from the date of diagnosis to the date of documented failure, disease progression, relapse or death from any cause.
Results
Response to first-line therapy
Eleven out of 14 patients achieved either a PR (10 patients) or a CR (one patient) after three courses of CHOP and were eligible for PBSCT ( Table 1 ). The median time from initial diagnosis to PBSCT was 4 months (range 4-5) ( Table 3) . Three patients (Nos 5, 6 and 11) had no response to initial chemotherapy. They were not transplanted and all three died of progressive disease despite salvage chemotherapy, 6, 7 and 12 months after diagnosis, respectively (Table 3 ).
Leukaphereses
PBSC collection was possible in all 11 cases eligible for high-dose therapy. A median number of two cytaphereses (range 2-3) was necessary to collect sufficient CFU-GM and CD34 + cells. The median number of CFU-GM collected was 9.1 × 10 4 /kg (range 3-88), and the median number of CD34 + cells was 3.2 × 10 6 /kg (range 1.9-9.58) ( Table 3) .
Autotransplantation (Table 3)
Haematological recovery: All patients engrafted. The median time to granulocyte (Ͼ0.5 × 10 9 /l) and platelet recovery (Ͼ25 × 10 9 /l) was 12 days (range 9-18) and 13 days (range 7-22), respectively. 
Tumor response, OS and EFS:
Three patients with progressive disease after initial chemotherapy were not transplanted and died of lymphoma. Four out of the remaining 11 patients relapsed 2, 7, 9 and 12 months after PBSCT, respectively. They all died from progressive disease despite salvage chemotherapy. Seven patients are alive and free from disease, 16-43 months after initial diagnosis (median 28). The acturial OS is 45.7% (±14.7% s.e.), and the actuarial EFS is 50% (±13.4% s.e.) at 3.5 years (Figure 1 ).
Discussion
The role of ASCT as front-line treatment in disseminated aggressive NHL in adult patients is debatable, [6] [7] [8] [9] and in most transplant programmes this procedure is restricted to patients aged р60 years. [4] [5] [6] [7] [8] [9] The aim of the present trial was not to answer the question of the place of ASCT as part of initial therapy in high-grade NHL, but to investigate the feasibility of such a procedure with PBSCT in patients aged 61-65 years.
Despite the small number of cases included in this series, this pilot study demonstrates that PBSCT can probably be performed in patients between 61 and 65 years of age. No toxic deaths, VOD, or cases of interstitial pneumonitis were observed. This approach may be feasible for three reasons: PBSC collection after G-CSF priming, CHOP therapy as the initial treatment, and the BEAM protocol as conditioning regimen. First, PBSC collected after G-CSF priming allowed prompt engraftment and reduced infections. This has also been reported in a recent trial of PBSC transplantation in elderly patients with relapsed or refractory NHL. 17 In this series of 13 patients, haematological recovery and transfusion requirements appeared to be similar to those observed in younger patients, and only one toxic death was reported. In the latter trial, as in our series, age by itself did not impair PBSC collection, allowing subsequent ASCT. Secondly, the CHOP regimen, which is considered the standard first-line treatment in high-grade NHL, 14 given as initial therapy did not induce any severe organ impairment that might have precluded high-dose therapy and ASCT in responding patients. Third, the BEAM regimen that we selected as conditioning therapy before PBSCT was well tolerated. A recent paper from Caballero et al 18 also described a very low transplant-related mortality (TRM) after the BEAM regimen, with 1.3% toxic deaths in a group of 79 patients transplanted with PBSC for NHL or Hodgkin's disease. However, the EBMT group described a higher TRM (13% within 90 days of transplantation) in patients aged 55 years and over treated for intermediateand high-grade NHL with high-dose therapy and autologous bone marrow transplantation (ABMT). 19 This was attributed to TBI-containing regimens as compared with chemotherapy-only regimens and the authors suggested that TBI-based conditioning protocols should be avoided in older patients. Another important difference, although haematological toxicity and use of growth factors were not specified in this paper, was that the source of stem cells was bone marrow (BM) and not PBSC. 19 Miller et al 20 also described an increased risk of TRM in patients aged 50-65 years as compared with younger patients in a singlecenter experience of 506 adult patients treated with ABMT. The authors mentioned that cyclophosphamide -TBI was the regimen most commonly used in older patients, and the TRM rate of 28% observed in patients aged 50-65 years was mainly related to preparative-regimen toxicity. Again, we feel that in elderly patients PBSC is preferable to BM, shortening the duration of aplasia, and that the BEAM regimen represents a tolerable conditioning protocol as compared to those regimens including TBI.
Autologous SCT as part of first-line therapy in patients with disseminated high-grade NHL is under investigation. [4] [5] [6] [7] [8] [9] This procedure might be beneficial to patient subgroups with poor-prognosis NHL. 7, 8 Age by itself has been identified as one of the most adverse prognostic factors, independently of other variables such as a high serum LDH level, tumor stage and performance status. 11 In patients over 60 years, considered as being in the high-intermediate risk group according to the International Index, the 2-year survival rate is estimated at 48% with conventional chemotherapy regimens. 11 Our results, in a small series of patients, are encouraging and may be compared to those achieved with standard chemotherapy, even if 20% of the patients could not proceed to PBSCT because of refractory disease.
Given the feasibility of high-dose therapy in patients aged 61-65 years observed in this series, we conclude that patients with intermediate-or high-grade disseminated NHL should not be excluded from trials evaluating the role of ASCT as part of initial treatment.
